A pharmaceutical titan born of Nordic heritage has quietly shed half its name, emerging simply as 'Novo' — a gesture that, in corporate life, rarely means only what it appears to mean. The Danish drugmaker, whose obesity medications reshaped both medicine and markets, now signals through this act of simplification that even extraordinary success can become its own kind of constraint. At a moment when competitors are closing ground and the landscape of weight-loss treatment is shifting with unusual speed, Novo's leadership is using a new name to announce something older and harder: the willingn